Neurenati Therapeutics

Neurenati Therapeutics is a biotechnology company dedicated to developing treatments for rare diseases. The first technology targets Hirschsprung's disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the absence of nerves in parts of the lower digestive tract. Neurenati has proposed an innovative therapy using growth factors to treat newborns with HSCR, thereby avoiding the need for surgery and its associated complications.